About Epitomics
Epitomics is a company based in Burlingame (United States) founded in 2001 by Weimin Zhu and Guo Liang Yu was acquired by Abcam in March 2012.. Epitomics has raised $16.21 million across 3 funding rounds from investors including Abcam, Sycamore Ventures and Amkey Ventures. Epitomics offers products and services including Primary Antibodies, ELISA Kits, and Cell Lines. Epitomics operates in a competitive market with competitors including GenScript, Sino Biological, Y-Biologics, Mabtech and Shanghai OPM Biosciences, among others.
- Headquarter Burlingame, United States
- Founders Weimin Zhu, Guo Liang Yu
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Abcam Limited
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Epitomics
Epitomics offers a comprehensive portfolio of products and services, including Primary Antibodies, ELISA Kits, and Cell Lines. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
High-specificity antibodies for detecting proteins in experiments.
Kits for sensitive immunoassay detection of various targets.
Validated cell lines for gene-editing and research applications.
Funding Insights of Epitomics
Epitomics has successfully raised a total of $16.21M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $2.11 million completed in January 2009. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series C — $2.1M
-
First Round
First Round
(04 Mar 2003)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2009 | Amount | Series C - Epitomics | Valuation |
investors |
|
| Apr, 2004 | Amount | Series C - Epitomics | Valuation |
investors |
|
| Mar, 2003 | Amount | Series B - Epitomics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Epitomics
Epitomics has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Abcam, Sycamore Ventures and Amkey Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Epitomics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Epitomics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Epitomics Comparisons
Competitors of Epitomics
Epitomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GenScript, Sino Biological, Y-Biologics, Mabtech and Shanghai OPM Biosciences, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Reagents and instruments are provided for life sciences research.
|
|
| domain | founded_year | HQ Location |
Reagents and kits are provided for clinical research applications.
|
|
| domain | founded_year | HQ Location |
Developer of antibodies for the treatment of multiple diseases
|
|
| domain | founded_year | HQ Location |
Antibodies and immunoassay kits are developed for research applications.
|
|
| domain | founded_year | HQ Location |
Antibody and vaccine culture media products are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Epitomics
Frequently Asked Questions about Epitomics
When was Epitomics founded?
Epitomics was founded in 2001 and raised its 1st funding round 2 years after it was founded.
Where is Epitomics located?
Epitomics is headquartered in Burlingame, United States. It is registered at Burlingame, California, United States.
Who is the current CEO of Epitomics?
Guo Liang Yu is the current CEO of Epitomics. They have also founded this company.
Is Epitomics a funded company?
Epitomics is a funded company, having raised a total of $16.21M across 3 funding rounds to date. The company's 1st funding round was a Series B of $3.1M, raised on Mar 04, 2003.
What does Epitomics do?
Epitomics is a biotechnology focussed on developing MAb technology and products. It developed rabbit MAb technology RabMAb for the creation of specific and custom rabbit MAbs that has potential in new MAb therapies. It claims that the MAbs produced from the technology acted as challenging targets such as splice variants, point mutations, species-specific orthologs, post-translational modifications, and small molecule compounds and has benefitted more than 550 institutions and 150 pharma and biotech companies. In March 2012, Abcam acquired Epitomics and since then working as its subsidiary.
Who are the top competitors of Epitomics?
Epitomics's top competitors include Sino Biological, GenScript and Y-Biologics.
What products or services does Epitomics offer?
Epitomics offers Primary Antibodies, ELISA Kits, and Cell Lines.
Who are Epitomics's investors?
Epitomics has 4 investors. Key investors include Abcam, Sycamore Ventures, Amkey Ventures, and Kenson Ventures.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.